Charles Benjamin Lee Btcs Inc. (BTCS) insider trading activity

Charles Benjamin Lee is Director of BTCS Inc.. Currently has a direct ownership of 135,892 shares of BTCS, which is worth approximately $379,138. The most recent transaction as insider was on Sep 30, 2025, when has been sold 2,588 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 136K

1.94% 3M change

18.97% 12M change

Total Value Held $379,138

Charles Benjamin Lee Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2025	BUY Grant, award, or other acquisition	-	2,588 Added 1.87%	135,892 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	-	5,682 Added 4.09%	133,304 Common Stock
Mar 31 2025	BUY Grant, award, or other acquisition	$12,501 $1.5 p/Share	8,334 Added 6.13%	127,622 Common Stock
Dec 31 2024	BUY Grant, award, or other acquisition	-	5,061 Added 4.07%	119,288 Common Stock
Sep 30 2024	BUY Grant, award, or other acquisition	$12,500 $1.16 p/Share	10,776 Added 8.62%	114,227 Common Stock
Sep 13 2024	BUY Grant, award, or other acquisition	$7,812 $1.08 p/Share	7,234 Added 6.54%	103,451 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	-	9,058 Added 8.6%	96,217 Common Stock

Mar 28 2024	BUY Grant, award, or other acquisition	-	7,103 Added 7.54%	87,159 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	-	7,669 Added 8.74%	80,056 Common Stock
Sep 30 2023	BUY Grant, award, or other acquisition	-	13,298 Added 15.52%	72,387 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	-	10,549 Added 15.15%	59,089 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	$12,501 $1.36 p/Share	9,192 Added 15.92%	48,540 Common Stock
Jan 02 2022	BUY Grant, award, or other acquisition	-	31,848 Added 44.73%	39,348 Common Stock
Apr 01 2021	BUY Grant, award, or other acquisition	-	75,000 Added 50.0%	75,000 Common Stock

Also insider at

MEIP

MEI Pharma, Inc. Healthcare

CBL